| | Advisory Board "We will surely get to our destination if we join hands." - Aung San Suu Kyi, Burmese political leader
DSEC is driven by an esteemed Advisory Board of industry executives who believe that idea sharing and discussion among safety leaders of different companies can make a positive impact in how the industry develops safer and more effective medicines for patients. Each board member is an active participant in DSEC agenda planning as well as serving in an executive position at a prominent biopharmaceutical company.
Jack A. Reynolds, DVM, DACVP, DACLAM & FIATP Chairman of the Advisory Board Drug Safety Executive Council
Herman Van Cauteren Senior Vice President / Global Head, GPCD Johnson & Johnson PRD
Jerry Fisher Senior Vice President, Office of the President Wyeth
Jim Green Senior Vice President, Preclinical and Clinical Development Sciences Biogen Idec
Eckhard von Keutz Senior Vice President, Global Head of Toxicology Bayer HealthCare AG
Marc Bonnefoi Global Head of Drug Safety Evaluation & Scientific Site Director for Sciences and Medical Affairs sanofi-aventis
Ruth Lightfoot Vice President, Comparative Biology & Safety Sciences Amgen
Gregg Lundeen Vice President, Toxicology Eli Lilly
Peter Moldeus Global Vice President, Drug Safety Evaluation AstraZeneca
Thomas Singer Global Head, Non Clinical Safety F. Hoffmann-La Roche
Paul Trennery Senior Vice President, Safety Assessments GlaxoSmithKline
James Macdonald Executive Vice President, Preclinical Development Schering-Plough |